Hangzhou Diagens Biotechnology (HKG:2526) reported an attributable loss of 55.9 million yuan for the first half of 2026, widening from a loss of 1.3 million yuan a year earlier, according to a Hong Kong bourse filing on Friday.
The medical imaging products maker's loss per share swelled to 0.66 yuan from 0.02 yuan a year ago.
Revenue increased year on year to 108.7 million yuan from 89.8 million yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.